NewsRx

Search our medical news database

Age-Related Macular Degeneration

Clinical results for EVIZON presented at meeting

Published in Health and Medicine Week, August 15th, 2005

Genaera Corp. (GENR) announced the presentation of clinical trial results from two U.S. phase II clinical trials with EVIZON (squalamine lactate) for the treatment of choroidal neovascularization associated with age-related macular degeneration (AMD), also known as "wet" AMD.

EVIZON is a systemically delivered anti-angiogenic drug being developed to treat AMD.

The presentations were held at the 23rd annual meeting of the American Society of Retina Specialists (ASRS) in Montreal, Quebec, Canada.

Brian P. Connolly, MD, retina research services, Wills Eye Hospital, Philadelphia, Pennsylvania, presented clinical trial results,...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook